Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome

Haemophilia

Volumn 14, Issue SUPPL. 3, 2008, Pages 49-55

  Collins, P ^a   Budde, U ^b   Rand, J H ^c   Federici, A B ^d   Kessler, C M ^e  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b Coagulation Laboratory   (Germany)

^c Montefiore   (United States)

^d UNIVERSITY OF MILAN   (Italy)

^e GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANTIFIBRINOLYTIC AGENT; AZATHIOPRINE; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DESMOPRESSIN; FIBRIN GLUE; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; LUPUS ANTICOAGULANT; PREDNISOLONE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RITUXIMAB; STAPHYLOCOCCUS PROTEIN A; STEROID; VON WILLEBRAND FACTOR;

ANTIBODY SCREENING; ANTIBODY TITER; ANTICOAGULATION; ARTICLE; BLEEDING; BLEEDING TENDENCY; BLOOD CLOTTING; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG REEXPOSURE; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; HEMOPHILIA; HUMAN; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; LOADING DRUG DOSE; LONG TERM CARE; LYMPHOPROLIFERATIVE DISEASE; MONOCLONAL IMMUNOGLOBULINEMIA; MONOTHERAPY; MYELOPROLIFERATIVE DISORDER; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; PATIENT EDUCATION; PLASMAPHERESIS; PRIORITY JOURNAL; RECURRENCE RISK; REMISSION; SHORT COURSE THERAPY; SINGLE DRUG DOSE; SYSTEMIC LUPUS ERYTHEMATOSUS; THERAPY DELAY; THROMBOSIS; TREATMENT OUTCOME; VON WILLEBRAND DISEASE;

ANGIOGRAPHY; AUTOANTIBODIES; CARDIOVASCULAR DISEASES; CLINICAL PROTOCOLS; HEMARTHROSIS; HEMOPHILIA A; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; RECOMBINANT PROTEINS; RECURRENCE; RISK FACTORS; VON WILLEBRAND FACTOR;

EID: 44249095099     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01745.x     Document Type: Article

References (34)

1. Collins P, Macartney N, Davies R, Lees S, Giddings J, Majer R. A population based, unselected, consecutive cohort of patients with acquired haemophilia A. Brit J Haematol 2004; 124: 86-90.
2. Collins PW, Hirsch S, Baglin TP et al. Acquired haemophilia A in the UK: a two year national surveillance study by UK Haemophilia Centre Doctors'Organisation. Blood 2007; 109: 1870-7.
3. Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost 1981; 45: 200-3.
4. Morrison AE, Ludlam CA, Kessler C. Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood 1993; 81: 1513-20.
5. Hay CR, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: A multicentre study. Thrombos Haemost 1997; 78: 1463-7.
6. Lottenberg R, Kentro TB, Kitchens CS. Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Int Med 1987; 147: 1077-81.
7. Hay CRM, Brown SA, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: A guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006; 133: 591-605.
8. Collins PW. Treatment of acquired hemophilia A. J Thromb Haemost 2007; 5: 893-900.
9. Sumner MJ, Geldziler BD, Pedersen M, Seremetis S. Treatment of acquired haemophilia with recombinant activated FVII: A critical appraisal. Haemophilia 2007; 13: 451-61.
10. Sallah S. Treatment of acquired haemophilia with factor eight inhibitor bypassing activity. Haemophilia 2004; 10: 169-73.
11. Tjonnfjord GE. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX: The updated Norwegian experience. Haemophilia 2004; 10(Suppl. 2): 41-5.
12. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 2002; 8: 83-90.
13. Varadi K, Negrier C, Berntorp E et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 2003; 1: 2374-80.
14. Sorensen B, Ingerslev J. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. J Thromb Haemost 2004; 2: 102-10.
15. Zeitler H, Ulrich-Merzenich G, Walger P, Dusing R, Vetter H, Brackmann HH. The modified Bonn Malmo protocol (MBMP) in the treatment of acquired haemophilia A. Dtsch Med Wochenschr 2006; 131: 141-7.
16. Freedman J, Rand ML, Russell O et al. Immunoadsorption may provide a cost-effective approach to management of patients with inhibitors to FVIII. Transfusion 2003; 43: L508-13.
17. Mudad R, Kane WH. DDAVP in acquired hemophilia A: Case report and review of the literature. Am J Hematol 1993; 43: 295-9.
18. Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: Review and meta-analysis focused on therapy and prognostic factors. Brit J Haematol 2003; 121: 21-35.
19. Schwartz RS, Gabriel DA, Aledort LM, Green D, Kessler CM. A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin. Blood 1995; 86: 797-804.
20. Stasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004; 103: 4424-8.
21. Field JJ, Fenske TS, Blinder MA. Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy. Haemophilia 2007; 13: 46-50.
22. Nemes L, Pitlik E. New protocol for immune tolerance induction in acquired hemophilia. Haematologica 2000; 85(Suppl. 10): 64-8.
23. Zeitler H, Ulrich-Merzenich G, Hess L et al. Treatment of acquired hemophilia by the Bonn-Malmo Protocol: Documentation of an in vivo immunomodulating concept. Blood 2005; 105: 2287-93.
24. Federici AB. Acquired von Willebrand Syndrome: An under- and misdiagnosed bleeding complication in patients with lympho- and myeloproliferative disorders. Semin Hematol 2006; 43: S48-58.
25. Simone JV, Cornet JA, Abildgaard CF. Acquired von Willebrand's syndrome in systemic lupus erythematosus. Blood 1968; 31: 806-12.
26. Veyradier A, Jenkins CS, Fressinaud E, Meyer D. Acquired von Willebrand syndrome: From pathophysiology to management. Thromb Haemost 2000; 84: 175-82.
27. Michiels JJ, Budde U, van der Planken M, van Vliet HH, Schroyens W, Berneman Z. Acquired von Willebrand syndromes: Clinical features, aetiology, pathophysiology, classification and management. Best Pract Res Clin Hematol 2001; 14: 401-36.
28. Federici AB, Rand JH, Bucciarelli P et al. Subcommittee on von Willebrand Factor: Acquired Don Willebrand syndrome: data from a International Registry. Thromb Haemost 2000; 84: 345-9.
29. Tiede A, Priesack J, Werwitze S et al. Diagnostic work-up of patients with acquired von Willebrand syndrome: A retrospective single-center cohort study. J Thromb Haemost 2008; 6: 569-76.
30. Mohri H, Motomura S, Kanamori H et al. Clinical significance of inhibitors in acquired von Willebrand syndrome. Blood 1998; 91: 3623-9.
31. Mannucci PM, Federici AB. Antibodies to von Willebrand factor in von Willebrand disease. In: Aledort LM, Hoyer LW, Reisner HM, White GC II, eds. Inhibitors to Coagulation Factors. New York: Plenum Press, 1995: 87-92.
32. Siaka C, Rugeri L, Caron C, Goudemand J. A new ELISA assay for diagnosis of acquired von Willebrand Syndrome. Haemophilia 2003; 9: 303-8.
33. Federici AB, Stabile F, Castaman G, Canciani MT, Mannucci PM. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: Comparison of three different therapeutic approaches. Blood 1998; 92: 2707-11.
34. Friederich PW, Wever PC, Briet E, Doorenbos CJ, Levi M. Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease. Am J Hematol 2001; 66: 292-4.